Management of Patients with Type V Hyperlipoproteinemia: An Uncommon Phenotype of Dyslipidemia with Chylomicronemia and Severe Hypertriglyceridemia

• Published in: Journal of personalized medicine Vol. 13; no. 1; p. 68
• Main Authors: Chang, Ya-Hui, Lin, Dai-Yi, Tsai, Chia-Ling, Liang, Chih-Hung, Yu, Yu-Ting, Hsieh, Yi-Lin, Chuang, Jen-Yu, Chen, Yi-Han, Yeh, Hung-I, Lin, Chao-Feng
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 28.12.2022; MDPI
• Subjects: Algorithms; Apolipoprotein B; Arteriosclerosis; Cardiovascular disease; Cardiovascular diseases; Cholesterol; Clinical medicine; Dyslipidemia; Enzymes; Fenofibrate; Genotype & phenotype; High density lipoprotein; Hormone replacement therapy; Hyperlipoproteinemia; Hypertriglyceridemia; Laboratories; Lipids; Lipoproteins; Low density lipoprotein; Medical imaging; Medical records; Metabolic disorders; National health insurance; Pancreatitis; Patients; Phenotypes; Plasma; Precision medicine; Statins; Thyroid gland; Variables; Japan; hypertriglyceridemia; type IV hyperlipoproteinemia; type V hyperlipoproteinemia
• ISSN: 2075-4426; 2075-4426
• DOI: 10.3390/jpm13010068

Hypertriglyceridemia (HTG) remains a risk-enhancing factor of atherosclerotic cardiovascular disease. We aimed to report real-world data on the management of patients with type V hyperlipoproteinemia (HLP5), an uncommon phenotype of dyslipidemia characterized by fasting chylomicronemia and severe HTG. Between July 2018 and May 2021, 90 patients with HTG, including 83 patients with type IV hyperlipoproteinemia (HLP4) and 7 patients with HLP5, were identified by plasma apolipoprotein B (apoB) and lipoprotein electrophoresis. Patients with HLP5 were younger, had higher total cholesterol (TC) (264.9 ± 26.7 mg/dL vs. 183.9 ± 26.1 mg/dL; p < 0.01) and higher triglyceride (TG) (1296.7 ± 380.5 mg/dL vs. 247.6 ± 96.1 mg/dL; p < 0.01), and had lower high-density lipoprotein cholesterol (HDL-C) (30.6 ± 4.8 mg/dL vs. 40.5 ± 8.7 mg/dL; p < 0.01) and lower low-density lipoprotein cholesterol (LDL-C) (62.9 ± 16.4 vs. 103.0 ± 21.1 mg/dL; p < 0.01) compared with patients with HLP4. Despite an aggressive use of statin and fenofibrate with greater reductions in TG (-65.9 ± 13.7% vs. -27.9 ± 30.5%; p < 0.01) following 6 months of treatment, patients with HLP5 had persistent HTG (440.1 ± 239.0 mg/dL vs. 173.9 ± 94.8 mg/dL; p < 0.01) and an increase in LDL-C (28.3 ± 57.2% vs. -19.5 ± 32.0%; p < 0.01) compared with patients with HLP4. Our findings highlight that the lack of novel TG-lowering medications and management guidelines remains an unmet medical need in patients with HLP5. Closely monitoring lipid profiles, full assessment of individual’s risk of cardiovascular disease, and emphasis on medication adherence are of clinical importance.